Loading viewer...
earnings
Format: PDF earnings
TGS presents Q2 2024 earnings results with total POC revenues of USD 215 million and strong contract inflow of USD 368 million. The presentation covers operational highlights including early sales performance, proprietary revenues, and the completion of the PGS transaction on July 1, 2024.
investor_presentation
15 Pages
earnings
22 Pages
Unknown
Teva Pharmaceutical Q1 2022 Results
earningsearnings
37 Pages
Teva Pharmaceutical Industries Ltd.